echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine's carmustine for injection was approved by the U.S. FDA

    Hengrui Medicine's carmustine for injection was approved by the U.S. FDA

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 22, Hengrui Medicine issued an announcement stating that it had recently received a notice from the US FDA that Hengrui Medicine’s application for a brief new drug for carmustine for injection declared to the US FDA has been approved.


    Carmustine is a nitrosourea compound that can be used as a single drug or combined with other approved chemotherapeutics in palliative care to treat the following aspects:

    (1) Brain tumors, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma and metastatic brain tumor;

    (2) Combined with prednisone to treat multiple myeloma;

    (3) Combined with other lymphomas and approved drugs to treat relapsed or refractory Hodgkin's lymphoma;

    (4) Combine other approved drugs to treat relapsed or refractory non-Hodgkin's lymphoma.


    Upon inquiry, the global sales of carmustine for injection in 2019 were approximately US$73.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.